Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
lnk0100 save search
Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
Published: 2024-03-22 (Crawled : 12:00) - prnewswire.com
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
lnk0100 first dermatitis pharmaceuticals study
Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
Published: 2023-12-20 (Crawled : 12:00) - prnewswire.com
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: 0.0%
lnk0100 first pharmaceuticals study
Lynk Pharmaceuticals Announces Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Ankylosing Spondylitis
Published: 2023-08-23 (Crawled : 14:00) - biospace.com/
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: -0.25%
H: 0.0%
C: 0.0%
lnk0100 positive treatment pharmaceuticals topline trial
Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis
Published: 2023-08-09 (Crawled : 12:00) - prnewswire.com
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
lnk0100 dermatitis positive treatment pharmaceuticals topline trial
Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed with LNK01004 in Phase Ib Clinical Study
Published: 2023-07-21 (Crawled : 12:00) - prnewswire.com
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: -0.12%
H: 1.57%
C: 1.2%
lnk0100 dermatitis pharmaceuticals study
Lynk Pharmaceuticals Announces First Cohort of Psoriatic Patients Dosed with LNK01004 in Phase Ib Clinical Study
Published: 2023-05-25 (Crawled : 12:00) - prnewswire.com
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.05%
lnk0100 pharmaceuticals study
LYNK's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis
Published: 2023-05-16 (Crawled : 12:00) - prnewswire.com
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: -0.31%
H: 0.75%
C: 0.18%
lnk0100 results
Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects
Published: 2023-04-04 (Crawled : 13:20) - biospace.com/
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: 0.08%
H: 1.27%
C: 0.97%
lnk0100 positive pharmaceuticals trial results
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
Published: 2022-12-05 (Crawled : 13:20) - biospace.com/
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: -0.29%
H: 0.56%
C: 0.24%
lnk0100 pharmaceuticals study ulcerative colitis
Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China
Published: 2022-08-03 (Crawled : 17:00) - biospace.com/
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: -1.64%
H: 0.0%
C: 0.0%
lnk0100 dermatitis approval china
Lynk Pharmaceuticals Announces the First Participant Dosed in Phase I Trial of LNK01004
Published: 2022-07-29 (Crawled : 12:20) - prnewswire.com
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
lnk0100 trial
Lynk Pharmaceuticals Announces Clinical Approval in China for Its Class I New Drug LNK01004
Published: 2022-04-22 (Crawled : 12:20) - prnewswire.com
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
lnk0100 drug approval china
Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001
Published: 2022-03-18 (Crawled : 14:00) - biospace.com/
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
lnk0100 partnership als commercialization 100
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis
Published: 2022-02-28 (Crawled : 14:30) - biospace.com/
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: 1.79%
H: 0.0%
C: 0.0%
lnk0100 als atopic dermatitis ces dermatitis derm 100
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis
Published: 2022-01-19 (Crawled : 13:00) - biospace.com/
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: 0.0%
lnk0100 als ces 100
Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001
Published: 2021-12-01 (Crawled : 15:30) - biospace.com/
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: -1.03%
H: 2.04%
C: 0.76%
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.